Immune ThrombocytopeniaMATACNCT06444477
Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
An observational study of Immune Thrombocytopenia and Immune Thrombocytopenic Purpura, run by University Hospital, Bordeaux at 20 sites in France.
Trial summary
The association between hematologic malignancies and ITP is well described, but this link is much less clear with solid cancers. In cases of ITP associated with cancers, specific cancer treatment can lead to remission or even cure of ITP. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Immune Thrombocytopenia, Immune Thrombocytopenic Purpura, Neoplasms
- What is being tested?
- ITP and cancer
- How many people
- 33 participants
- Where
- 20 sitesFrance
- Study dates
- 13 Aug 2024to 15 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with a definite diagnosis of both ITP and cancer
Who may be able to join
- Adult patients with a definite diagnosis of both ITP and cancer;
- Synchronous diagnosis of ITP and cancer;
- Onset of ITP occurring 6 months before or after the diagnosis of cancer.
Who cannot join
- None
Trial locations and contacts
20 sites in 1 country.
20 sites in 1 country
France20 sites
AP-HP Hôpital Jean Verdier service de médecine interne
Bondy
CHU de Clermont-Ferrand - service de médecine interne
Clermont-Ferrand
AP-HP Hôpital Mondor service de médecine interne
Créteil
AP-HP Hôpital Bicêtre service de médecine interne
Le Kremlin-Bicêtre
CHU de Lille - service d'Hématologie
Lille
HCL - service d'Hématologie
Lyon
AP-HM Hôpital la Timone - service de médecine interne
Marseille
CHU de Montpellier - service d'Hématologie
Montpellier
CHRU de Nancy - service de Médecine Interne et Immunologie Clinique
Nancy
CHU de Nantes - service de médecine interne
Nantes
CHRU d'Orléans - service de Médecine interne
Orléans
CHRU d'Orléans - service de réanimation
Orléans
AP-HP Hôpital Bichat service de médecine interne
Paris
AP-HP Hôpital Saint-Antoine service de médecine interne
Paris
AP-HP Hôpital Saint-Louis service immuno-hématologie
Paris
CHU de Bordeaux Service de Médecine Interne et Maladies Infectieuses
Pessac
CHU de Poitiers - service de médecine interne
Poitiers
CHRU de Strasbourg - service de médecine interne
Strasbourg
CHU de Toulouse - service de médecine interne
Toulouse
CHU de Tours - service de médecine interne
Tours
About this study
The association between hematologic malignancies and ITP is well described, but this link is much less clear with solid cancers. In cases of ITP associated with cancers, specific cancer treatment can lead to remission or even cure of ITP. Thus, our hypothesis was that chronic expression of GPIIB by tumor cells could have initiated an autoimmune loop against GPIIB, leading to the onset and perpetuation of ITP.
Read the detailed description
Autoimmune thrombocytopenia, also known as immune thrombocytopenic purpura (ITP), is a rare autoimmune disease characterized by platelet destruction and impaired production, posing a life-threatening risk due to bleeding complications. The pathophysiology of ITP involves complex mechanisms, including both defective platelet production and auto-reactivity of B and T lymphocytes leading to the production of autoantibodies against platelets, found in 35 to 55% of cases. Additionally, in the context of neoplasia, some patients may develop varying degrees of thrombocytopenia, exacerbating morbidity and mortality. A multicenter, retrospective study will collect data from routine care, including birth date, gender, biological parameters related to ITP, dates of treatment initiation and diagnosis of ITP and cancer, types of treatments, and outcomes such as survival or death, without additional medical interventions or appointments.
- Being tested
- ITP and cancer
- Keywords
- Proteomics, Mortality, Side Effects, Multicenter, Retrospective
- Medical subject headings
- Purpura, Thrombocytopenic, Idiopathic, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ITP and cancerOther
ITP and cancer
| Study group | Role | What they receive |
|---|---|---|
| Patients with a definite diagnosis of both ITP and cancer | Not described Receives: Other: ITP and cancer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Remission rate of ITP at 6 months after specific cancer treatment
Measured: At baseline (Day 0)
Secondary outcomes (7)
All-cause mortality
Measured: At baseline (Day 0)
Side effects related to ITP and its treatment
Measured: At baseline (Day 0)
Side effects related to its treatment
Measured: At baseline (Day 0)
Clinical description of the characteristics of ITP associated with a diagnosis of solid cancer
Measured: At baseline (Day 0)
Biological description of the characteristics of ITP associated with a diagnosis of solid cancer
Measured: At baseline (Day 0)
Demographic description of the characteristics of ITP associated with a diagnosis of solid cance
Measured: At baseline (Day 0)
Therapeutic description of the characteristics of ITP associated with a diagnosis of solid cance
Measured: At baseline (Day 0)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2024
- Study start13 Aug 2024
- Primary completion15 Sep 2025
- Study completion15 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Immune ThrombocytopeniaStudies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 33 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Etienne RIVIERE, MD, Principal investigator, University Hospital, Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06444477
- Sponsor's protocol ID
- CHUBX 2024/16
- Acronym
- MATAC
- Status last verified
- Jan 2026
- First submitted
- 14 May 2024
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
- ClinicalTrials.gov ID
- NCT06444477
- Acronym / sponsor ID
- MATAC / CHUBX 2024/16
- Keywords
- Proteomics, Mortality, Side Effects, Multicenter, Retrospective
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 33 participants (actual)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- 13 Aug 2024 (actual)
- Primary completion
- 15 Sep 2025 (actual)
- Study completion
- 15 Sep 2025 (actual)
- First posted
- 5 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The association between hematologic malignancies and ITP is well described, but this link is much less clear with solid cancers. In cases of ITP associated with cancers, specific cancer treatment can lead to remission or even cure of ITP. Thus, our hypothesis was that chronic expression of GPIIB by tumor cells could have initiated an autoimmune loop against GPIIB, leading to the onset and perpetuation of ITP.
Detailed description
Autoimmune thrombocytopenia, also known as immune thrombocytopenic purpura (ITP), is a rare autoimmune disease characterized by platelet destruction and impaired production, posing a life-threatening risk due to bleeding complications. The pathophysiology of ITP involves complex mechanisms, including both defective platelet production and auto-reactivity of B and T lymphocytes leading to the production of autoantibodies against platelets, found in 35 to 55% of cases. Additionally, in the context of neoplasia, some patients may develop varying degrees of thrombocytopenia, exacerbating morbidity and mortality. A multicenter, retrospective study will collect data from routine care, including birth date, gender, biological parameters related to ITP, dates of treatment initiation and diagnosis of ITP and cancer, types of treatments, and outcomes such as survival or death, without additional medical interventions or appointments.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with a definite diagnosis of both ITP and cancer | – | Other: ITP and cancer |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with a definite diagnosis of both ITP and cancer
Key inclusion criteria (3 listed)
- Adult patients with a definite diagnosis of both ITP and cancer;
- Synchronous diagnosis of ITP and cancer;
- Onset of ITP occurring 6 months before or after the diagnosis of cancer.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ITP and cancerITP and cancer | Other | Patients with a definite diagnosis of both ITP and cancer |
Primary outcome
Remission rate of ITP at 6 months after specific cancer treatment
Time frame: At baseline (Day 0)
7 secondary outcomes
All-cause mortality
Time frame: At baseline (Day 0)
Side effects related to ITP and its treatment
Time frame: At baseline (Day 0)
Side effects related to its treatment
Time frame: At baseline (Day 0)
Clinical description of the characteristics of ITP associated with a diagnosis of solid cancer
Time frame: At baseline (Day 0)
Biological description of the characteristics of ITP associated with a diagnosis of solid cancer
Time frame: At baseline (Day 0)
Demographic description of the characteristics of ITP associated with a diagnosis of solid cance
Time frame: At baseline (Day 0)
Therapeutic description of the characteristics of ITP associated with a diagnosis of solid cance
Time frame: At baseline (Day 0)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
Related trials for Immune Thrombocytopenia
RecruitingPhase 2
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
RecruitingPhase 1/2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
RecruitingPhase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
RecruitingPhase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Immune Thrombocytopenia
RecruitingPhase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Etienne RIVIERE, MD principal investigator
University Hospital, Bordeaux
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Immune Thrombocytopenia and Immune Thrombocytopenic Purpura, run by University Hospital, Bordeaux at 20 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Remission rate of ITP at 6 months after specific cancer treatment (time frame: At baseline (Day 0)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.